期刊文献+

原发舌根非霍奇金淋巴瘤的临床分析 被引量:4

在线阅读 下载PDF
导出
摘要 原发头颈部的非霍奇金淋巴瘤(non—Hodgkin lymphoma NHL)约有一半以上起源于韦氏环(waldeyer ring WR),韦氏环也叫咽淋巴环,包括舌根、双侧扁桃体、鼻咽和软腭。韦氏环属于结内部位还是结外部位目前尚有争议。在我国原发于WR的NHL的发病率高于西方,可占同期非霍奇金淋巴瘤《NHL)的23.5%,其中以扁桃体部位最常见,约占WR发病率的37%~62%,国内外对其报道较多。而原发于舌根的NHL较少见,
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2008年第19期1106-1108,共3页 Chinese Journal of Clinical Oncology
  • 相关文献

参考文献10

  • 1Gurkaynak M, Cengiz M, Akyurek S, et al. Waldeyer's ring lymphomas: treatment results and prognostic factors[]]. Am J Clin Oncol, 2003, 26(5): 437-440.
  • 2李晔雄,高远红,袁智勇,赵路军,刘新帆,余子豪.国际预后指数在韦氏环非霍奇金淋巴瘤的预后意义[J].中华放射肿瘤学杂志,2002,11(2):105-110. 被引量:34
  • 3Ezzat AA, Ibrahim EM, El Weshi AN, et al. Localized non--Hodgldn's lymphoma of Waldeyer's ring: clinical features, management,and prognosis of 130 adult patients[J]. Head Neck, 2001, 23(7): 547--558.
  • 4秦海燕,胡伟汉,李小芳,潘燚,张国义.原发性扁桃体NHL临床特点和预后分析[J].现代肿瘤医学,2007,15(1):15-18. 被引量:4
  • 5赵路军,李晔雄,袁智勇,高远红,刘新帆,余子豪.原发于舌根非霍奇金淋巴瘤临床特点及预后[J].中华放射肿瘤学杂志,2003,12(1):21-24. 被引量:8
  • 6Aviles A, Delgado S, Ruiz H, et al. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy[J]. EurJ Cancer B Oral Oncol, 1996, 32B(1): 19-23.
  • 7Nishioka T, Tsuchiya K, Nishioka S, et al. Pilot study of modified version of CHOP plus radiotherapy for early--stage aggressive non-Hodgkin's lymphoma of the head and neck[]]. Int J Radiat Oncol Biol Phys, 2004, 60(3): 847--852.
  • 8Miller TP, Dahlberg S,Cassady JR,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate--and high--grade non--Hodgkin's lyrnphoma[J]. N Engl J Med, 1998, 339(1): 21-26.
  • 9Isikdogan A, Ayyildiz O, Buyukcelik A, et al. Non-Hodgkin's lymphoma in southeast Turkey: clinicopathologic features of 490 cases[J]. Ann Hematol, 2004, 83(5): 265-269.
  • 10林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量:49

二级参考文献45

  • 1林桐榆,张红雨,黄岩,管忠震,沈悌,石远凯,朱军,克晓燕,王华庆,沈志祥,于世英,刘霆,施笑利.R-CHOP与CHOP方案治疗初治弥漫大B细胞型淋巴瘤在中国的多中心随机对照研究[J].癌症,2005,24(12):1421-1426. 被引量:49
  • 2Coiffier B, Lepage E. Prognosis of aggressive lymphomas :a study of five prognostic models with patients included in the LNH-84 regimen [J]. Blood, 1989,74(2) :558-564.
  • 3Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994,83(2) :435-445.
  • 4Coiffier B, Haioun C, Ketterer N, et al. Rituximab (antiCD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma., a multicenterphase Ⅱ study [J]. Blood, 1998,92(6) : 1927-1932.
  • 5The Non-Hodgkin's Lymphoma Pathologic Classification Project.National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage [J]. Cancer, 1982,49(10) : 2112-2135.
  • 6Tedder TF, Engel P. CD20:a regulator of cell-cycle progression of B lymphocytes [J]. Immunol Today, 1994,15(9):450-454.
  • 7Demidem A,(IDEC-C2B8)lymphoma cellCancer BiotherLam T, Alas S, et al. Chimeric anti-CD20 monoclonal antibody sensitizes a B cell line to cell killing by cytotoxic drugs [J].Radiopharm, 1997, 12(3) : 177-186.
  • 8Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [J]. N Engl J Med, 2002,346(4) :235-242.
  • 9McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond totreatment program [J]. J Clin Oncol, 1998,162833.a four-dose(8):2825-2833.
  • 10Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD [J]. Ann Intern Med,1986, 104(6) : 757-765.

共引文献89

同被引文献34

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部